Request Demo
Aslan sells Japanese rights to would-be Dupixent rival for $12M
Phase 1Phase 2License out/inDrug Approval
Zenyaku plans to start a phase 1 trial of eblasakimab in Japan in the first half of next year
Zenyaku Kogyo is lining up a challenge to eblasakimabRegeneron’s blockbuster Dupixent in Japan, paying Aslan Pharmaceuticals $12 million upfront for local rights to a midphase eczema drug candidate.
Zenyaku Kogyos anti-IL-13 receptor antibodSanofisakimRegeneron molecule to adDupixente unmet needs thatAslan Pharmaceuticalsto address. With its market cap languishing at $64 meczema, Aslan is yet to convince investors it is on to a winner but the Singapore-based company has persuaded Zenyaku to write a check and add its candidate to a Japanese portfolio that features products including Rituxan.
Aslanku is payianti-IL-13 receptor antibodyheblasakimab develop and commercialize eblasakimab in atopic Dupixentis, the most common form of eczema, and all other indications in Japan. Aslan will receive $3 million more if it meets pre-agreed conditions related to a phase 2b trial.ZenyakuRituxan
Zenyakuditions cover the data readout and delivery of the clinical study report, aeblasakimabstonatopic dermatitis of a potential series of eczemating paydays for Aslan. Overall, ZenyaAslan on the hook for up to $29.5 million in development milestones and up to $94 million in commercial milestones.
In return for the outlay, the Japanese drugmaker will gain regional rights to a molecule that is designed to prevent signaling through IL-4 and IL-13. Aslan thinks (PDF) its approZenyakuld more efficiently block IL-13 signaling than Dupixent, and thereby potentially have improved dose frequency and efficacy. With only a subset of patients having optimal responses to Dupixent, there is scope to improve on the drug.
Whether eblasakimab can seize the opportunity created by the limitations of Dupixent remains to be seen. Aslan expects to have topline IL-4 fromIL-13ase 2b clinical trial of its antibody in biologic-naïve atopic IL-13titis patients eDupixentt month. Midphase data in patients previously treated with Dupixent are due in the first quarter of next year.Dupixent
Zenyaku eblasakimabart a phase 1 trial of eblasakimab in Japan in the first Dupixentnext year. Aslan has Aslanan option to re-acquire the rights to its IL-13 antibody in Japan at any time.atopic dermatitisDupixent
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.